PE20210412A1 - Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano - Google Patents
Moduladores de sting (estimulador de genes de interferon) a base de ciclopentanoInfo
- Publication number
- PE20210412A1 PE20210412A1 PE2020001412A PE2020001412A PE20210412A1 PE 20210412 A1 PE20210412 A1 PE 20210412A1 PE 2020001412 A PE2020001412 A PE 2020001412A PE 2020001412 A PE2020001412 A PE 2020001412A PE 20210412 A1 PE20210412 A1 PE 20210412A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclopentane
- stimulator
- interferon genes
- sting
- sting modulators
- Prior art date
Links
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title abstract 4
- 108010050904 Interferons Proteins 0.000 title abstract 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula (I), o una sal farmaceuticamente aceptable del mismo, donde: cada J es independientemente oxigeno (O) o azufre (S); R1 y R2 se seleccionan de (i), (ii), entre otros; W y X son OH, SH, entre otros; cada Y o Z se seleccionan independientemente de hidrogeno, halogeno, entre otros. Son compuestos especificos: (a), (b), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son activadores de STING (Estimulador de Genes de Interferon) a base de ciclopentano, utiles en el tratamiento del crecimiento celular anormal, tal como el cancer.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643467P | 2018-03-15 | 2018-03-15 | |
| US201862666204P | 2018-05-03 | 2018-05-03 | |
| US201862742532P | 2018-10-08 | 2018-10-08 | |
| US201962809990P | 2019-02-25 | 2019-02-25 | |
| PCT/IB2019/052009 WO2019175776A1 (en) | 2018-03-15 | 2019-03-12 | Cyclopentane-based modulators of sting (stimulator of interferon genes) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210412A1 true PE20210412A1 (es) | 2021-03-04 |
Family
ID=66103038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001412A PE20210412A1 (es) | 2018-03-15 | 2019-03-12 | Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10538542B2 (es) |
| EP (1) | EP3765474B1 (es) |
| JP (1) | JP7266942B2 (es) |
| KR (1) | KR20200131878A (es) |
| CN (1) | CN111918871A (es) |
| AU (1) | AU2019234043A1 (es) |
| BR (1) | BR112020018593A2 (es) |
| CA (1) | CA3093631C (es) |
| CL (1) | CL2020002352A1 (es) |
| CR (1) | CR20200382A (es) |
| DO (1) | DOP2020000160A (es) |
| EC (1) | ECSP20057847A (es) |
| ES (1) | ES2923298T3 (es) |
| IL (1) | IL277278A (es) |
| MA (1) | MA52012A (es) |
| MX (1) | MX2020009587A (es) |
| NI (1) | NI202000058A (es) |
| PE (1) | PE20210412A1 (es) |
| PH (1) | PH12020551486A1 (es) |
| RU (1) | RU2020130048A (es) |
| SG (1) | SG11202008102VA (es) |
| TW (1) | TWI741268B (es) |
| UY (1) | UY38145A (es) |
| WO (1) | WO2019175776A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| GEP20237572B (en) * | 2019-09-25 | 2023-11-27 | Pfizer | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| KR20170015353A (ko) * | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Ｓｔｉｎｇ의 조절제로서 사이클릭 디뉴클레오타이드 |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US10538542B2 (en) * | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
-
2019
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-11 TW TW108108048A patent/TWI741268B/zh not_active IP Right Cessation
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/ja active Active
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/ko not_active Application Discontinuation
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/es unknown
- 2019-03-12 CA CA3093631A patent/CA3093631C/en active Active
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/zh active Pending
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/en active Application Filing
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/es unknown
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/pt not_active IP Right Cessation
- 2019-03-12 CR CR20200382A patent/CR20200382A/es unknown
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/en active Active
- 2019-03-12 ES ES19717149T patent/ES2923298T3/es active Active
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-12 MA MA052012A patent/MA52012A/fr unknown
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/ru unknown
- 2019-03-13 UY UY38145A patent/UY38145A/es not_active Application Discontinuation
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/es unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/es unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/es unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/es unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210412A1 (es) | Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano | |
| PE20181297A1 (es) | Dinucleotidos de purino ciclico como moduladores de sting | |
| PE20200696A1 (es) | Moduladores de moleculas pequenas de sting humana | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| CL2020003260A1 (es) | Compuestos de naftiridinona sustituidos útiles como activadores de células t | |
| PE20170662A1 (es) | Compuestos de aminopiridiloxipirazol | |
| CL2022000485A1 (es) | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t | |
| CO2017013432A2 (es) | Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones | |
| PE20151090A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| PE20221487A1 (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t | |
| DOP2016000316A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| PE20171177A1 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CU20160180A7 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| MX2021011608A (es) | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. | |
| ECSP23045506A (es) | DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| PE20121507A1 (es) | Derivados de (heterociclo-piperidina condensada)-(piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona como inhibidores de p75 | |
| AR044193A1 (es) | Compuesto de 1,2,4-triazol-5-ona, composicion farmaceutica que lo comprende, su uso para prepararla y kit que comprende dicho compuesto | |
| PE20061042A1 (es) | Derivados de 5-fenilpirimidina como agentes para el tratamiento del cancer | |
| UY39303A (es) | Inhibidores de mutación her2 | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |